FDA approves Leqembi™ (Lecanemab–IRMB) under the accelerated approvalpathway for the treatment of Alzheimer’s disease
January 6, 2023FDA Approves use of Rybelsus (semaglutide) as a First-Line Option for Adults withType 2 Diabetes
January 12, 2023January 11, 2023 - Airsupra (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.
The approval by the Food and Drug Administration (FDA) was based on results from the MANDALA and DENALI Phase III trials. In MANDALA, Airsupra significantly reduced the risk of severe exacerbations compared to albuterol in patients with moderate to severe asthma when used as an as-needed rescue medication in response to symptoms. In DENALI, Airsupra significantly improved lung function compared to the individual components albuterol and budesonide in patients with mild to moderate asthma.
Airsupra, a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti- inflammatory inhaled corticosteroid (ICS) is being developed by AstraZeneca and Avillion.
Possible side effects can include serious allergic reactions, heart problems, worsening of trouble breathing and possible death from too much use of Airsupra.